福仕生物工程

Fosse Bio-Engineering Development Limited is a Hong Kong-based biotechnology company focused on the development and commercialization of oral insulin products. The company's flagship candidate is an oral insulin enteric-coated soft capsule (胰岛素肠溶胶丸) developed in collaboration with Tsinghua University. This product is designed to deliver insulin orally by protecting it from gastrointestinal degradation, offering a non-invasive alternative to traditional insulin injections. Fosse Bio-Engineering is currently conducting Phase IIIb clinical trials in China for patients with type 2 diabetes who have poor glycemic control with oral hypoglycemic agents. The company operates as a subsidiary of Starcoin Group Limited (formerly Innovative Pharmaceutical Biotech Limited).